Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Teriflunomide to its portfolio of oral medications. The drug is formulated as a film-coated tablet. Accord's Teriflunomide is therapeutically equivalent to Sanofi Genzyme's Aubagio® and is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Accord's product is offered in a 14mg tablet and a 7mg tablet and is currently available to ship.
Teriflunomide is approved by the FDA for use as an immunomodulatory agent in patients 18 and older to decrease the frequency and severity of disease flare-ups, called relapses, to prevent new symptoms or a worsening of old symptoms related to the disease's neurologic impact.1
"We're proud to add Teriflunomide to our portfolio. This is an important oral therapy for the millions of patients living with relapsing MS," said Accord Healthcare U.S. Vice President of Sales Jim Brown. "Generic medicine allows broad access to effective therapy, to help improve disease course and potentially slow progression of MS."
Important Safety Information: Teriflunomide can cause serious liver problems, including liver failure that may be life-threatening or require a liver transplant.2 The risk of developing serious liver problems may be higher for those with liver problems or who take other medicines that also affect the liver. Teriflunomide is contraindicated for use in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm.2 Teriflunomide may stay in the blood for up to two years after taking it.2
Further information about safety, potential side effects, and full prescribing information can be found here at Accord Healthcare US.
Teriflunomide belongs to a class of drugs known as immunomodulatory agents or disease-modifying therapy. It works by inhibiting an enzyme essential to a biochemical pathway involved in the proliferation of lymphocytes, a type of white blood cell. Fewer activated lymphocytes reduces inflammation and immune reactivity to reduce relapse rates and to protect against brain volume loss resulting from inflammatory attacks on the nerve cells in the brain.1,3
Teriflunomide was first approved by the FDA in 2012.1
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!